Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Molecular docking of SARS-COV-2 Spike epitope sequences identifies heterodimeric peptide-protein complex formation with human Zo-1, TLR8 and brain specific glial proteins

Subhajit Dasgupta a,b,*, Mausumi Bandyopadhyay c

a Regenerative Neuro Immune Research Institute of South Carolina, Charleston, United States
b NeuroDrug Research LLC, Charleston, SC, United States
c Department of Natural Sciences, Biology Division, Trident Technical College, North Charleston, SC, United States

ARTICLE INFO

Keywords:
Spike epitopes
SARS-COV-2
Glia
Blood brain barrier
Brain

ABSTRACT

SARS-COV-2 infection causes severe respiratory tract illness leading to asphyxia and death. The onset of infection is associated with loss of smell, blurred vision, headache with bronchopulmonary symptoms. The clinical observations of neurological abnormalities lead us to address the question, does the virus enter into brain and what is the underlying mechanism of brain infection? The working hypothesis is, SARS-COV-2 Spike epitopes modify blood brain barrier and infect glial cells to induce brain inflammation in genetically diverse human population. The hypothesis is tested by determining binding or interacting ability of virus Spike epitope peptides M1Lys60 and Ala240Glu300 with human toll-like receptor 8 (TLR 8), brain targeted Vascular Cell adhesion Molecules (VCAM1) proteins, Zonula Occludens (ZO), glial cell specific protein NDRG2 and Apo- S100B. The molecular dynamic experiments are performed, and root mean square deviation (RMSD) values are determined for interactions between the Spike peptides and selected proteins. The observations demonstrate formation of heterodimeric complex between the epitope peptides and selected protein structures. The viral epitopes have ability to bind with HLA-DRB1 15:01, 07:01 or 03.01 alleles thus found immunogenic in nature. The observations altogether suggest entry of these Spike protein epitopes into human brain causes inflammation.

Introduction/background

Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) causes recent pandemic with heightened mortality rate all over the world. Acute respiratory distress (ARD) with uncontrolled surge of cytokines is found to worsen the disease condition. The viral infection causes lung collapse with pneumonia [1,2] and cardiovascular failure [3]. The genetic mark up with susceptibility of infection in population was not known until recent genome wide association study (GWAS) which suggests 3p21.31 gene cluster is critical for SARS-COV-2 infection with respiratory failure [4]. Several investigations [5–7] also indicated possible genetic factors for determining hosts’ susceptibility to SARS-COV-2. Progressive infection causes kidney malfunction [8] and multi-organ failure [9]. The meta-analysis of COVID-19 patients in pandemic demonstrates close association with neuropsychiatric disorders [10]. The presence of virus particles in cerebrospinal fluid has been demonstrated from infected patients [11,12] which indicates presence of the virus into central nervous system. It is reported that SARS-COV-2 infection activates astrocytes and microglia in patients [13]. Though mechanism is still not clear. We identified unique Spike epitopes which have binding affinity to HLA-DRB1 alleles 15:01; 07:01 and 03:01 with variable immunogenicity to T helper cells. The brain receptor binding efficacy of these viral peptides are tested by demonstration of heterodimeric formation with selected human brain targeted proteins. The mapping of viral receptors in human brain and immune therapy approach to block these virus epitopes are currently underway.

The hypothesis/theory

Our working hypotheses are two folds; we propose (a) SARS-COV-2 spike epitope peptides modify blood brain barrier proteins and enter into brain cause inflammation; and (b) Viral spike epitope peptides induce activated T helper cells recognized by HLA-DRB1 alleles in genetically diverse human population leading to chronic brain
inflammation and neurodegeneration.

Evaluation of hypothesis/idea

The specific interaction patterns between virus spike epitope sequences and human brain targeted proteins are still not clear. It has been reported that, seven members of human Corona Virus family (hCOV) : SARS-COV, SARS-COV-2, MERS-COV, HCoV-OC43, HCoV-229E, HCoV-HKU1 and HCoV-NL63 are related to each other and possibly infect human central nervous system (CNS) [12]. Virus infection causes alteration in blood brain barrier integrity [14,15]. The postmortem analysis of COVID-19 patients demonstrates presence of activated astrocytes, microglia and cytotoxic T cells in olfactory bulb, brain stem and cerebellum [13,16,17].

Empirical data

We selected two Spike peptides with amino acid sequences 1–60 (M1Lys60) and 241–300 (Ala240Glu300) (NH2-terminal sequences) to determine their binding efficacy with brain receptor proteins. The viral peptides are found to bind with HLA-DRB1 alleles 03:01, 07:01 and 15:01 to a variable extent (Table 1) (IEDB epitope analysis tools). The observations presented in Table 1 suggested that viral peptides are immunogenic in nature. We performed molecular dynamics and docking experiments (md) using AutoDock Tools (Script, La Jolla), PyMol software systems (US), to determine interaction patterns between membrane bound alpha helical SARS-COV-2 Spike epitopes (PDB: Spike Chain_A_1-60 and Spike Chain_A_241-300) (Identified epitope peptides, Subhajit Dasgupta) and selected protein sequences : human tight junction protein Zo (PDB: 3SHU), integrin VCAM1 (PDB: 1VSC) [18], innate immune responder TLR8 (PDB: 3W3N) [19], glial protein NDRG2

| N-terminal Spike peptides | Immunogenic CD4 epitope(s) | IEDB combined score | Epitope binding efficacy with HLA-DRB1 alleles (IC50 nM) |
|---------------------------|---------------------------|--------------------|---------------------------------|
| Peptide A: 1-60           | LVSLISVLYL                | 52.20664           | 42                              |
|                           | LLPSVILMGIC               | 56.00644           | 42                              |
| Peptide C: 241-300        | ITRFQRTLAA               | 49.766             | (351/) 42 90                    |
|                           |                           |                    | (452/) 100.3                    |
|                           |                           |                    | 242.9 100.3                    |

‡ The IEDB epitope analysis tool is used to determine IC(50) values; IC (50) value less than 50 nM is considered as high affinity binding of peptide with HLA-DRB1 allele; IC (50) greater than 50 less than 500 nM is intermediate affinity. IC (50) greater than 500 nM less than 5000 nM is considered as low to poor affinity or no affinity. The core peptides are assessed for their affinity profile with alleles.

Table 1: SARS-COV2 N-terminal Spike peptide epitopes efficiently bind with HLA-DRB1 alleles and demonstrate CD4 cell immunogenicity.

Fig. 1. SARS-COV-2 Spike epitope peptides (amino acid sequences 1–60 and 241–300) form complex with blood brain barrier protein Zonula Occludens and integrin vascular cell adhesion molecule (VCAM). The molecular docking experiments were performed to determine interaction between alpha helical SARS-COV-2 Spike epitope peptides (PDB id: Spike Chain_A_1-60 and Spike Chain_A_241-300) with (A) Zonula Occludens (Zo ; PDB id: 3SHU). RMSD for md run with Spike Chain_A_241-300 is 2.907 Angstrom. Inset figure shows secondary protein structures interacting with each other in docking experiment. (B) VCAM (PDB id: 1VSC) to form heterodimeric complex. RMSD for md run with Spike Chain_A_1-60 is 5.605 Angstrom and Spike Chain_A_241-300 is 5.065 Angstrom. Inset figure shows secondary protein structures interacting with each other in docking experiment. The md plot shows FRAME/sec value @30 frames per sec run for 120x 10^9 nsec Rendering time. The interacting protein sequences are in highlighted box and provided in both the figures.
The md experiments were performed by using protein database (PDB) format of Spike peptides and selected proteins. We aligned the PDB formatted Spike peptides with each of selected brain derived peptides considering outlier rejection in 10 cycles and cut off value 2 Angstrom unit. The md run was set for 2 min \((120 \times 10^9\) nsec), 30 Frames per second with ray tracing parameter and each aligned Spike peptide as mobile selection for each selected host protein (target selection). We determined root mean square deviation (RMSD) for the md run.

**Fig. 2.** SARS-COV-2 Spike peptide (amino acid sequence 241–300) form heterodimeric complex with human toll-like receptor 8 (hTLR8). The molecular docking experiments were performed to determine interaction between alpha helical SARS-COV-2 Spike epitope peptide PDB id: Spike Chain_A_241–300 with human toll-like receptor 8 (TLR8). RMSD for md run with Spike Chain_A_241-300 is 14.096 Angstrom. Inset figure shows secondary protein structures interacting with each other in docking experiment. The md plot shows Frame/sec value @30 frames per sec run for 120x 10(9) nsec Rendering time. The interacting protein sequences are shown in the figure.

**Fig. 3.** SARS-COV-2 Spike epitope peptides form complex with astrocyte activation protein NDRG2 and calcium modulator protein Apo-S100B. The molecular docking experiments demonstrate SARS-COV-2 alpha helix peptides with amino acid sequence 1–60 and 241–300 form dimeric complex with (A) NDRG2. The RMSD value for md run with Spike Chain_A_1-60 and NDRG2 is 5.495 Angstrom and md run with Spike Chain_A_241-300 and NDRG2 is 7.857 Angstrom. and (B) Apo-S100B. The molecular dynamic run between Spike Chain_A_1-60 and Apo-S100B shows RMSD value 0.539 Angstrom. The md run between Spike Chain_A_241-300 and Apo S100B shows RMSD value 0.777 Angstrom unit. Inset figure shows secondary protein structures interacting with each other in docking experiment (Apo-S100B one isomer out of 20 is taken for md run experiment). The md plot for each individual interaction shows Frame/sec value @30 frames per sec run for 120x 10(9) nsec Rendering time. The highlighted interacting protein sequences are...
square deviation (RMSD) value (Angstrom) for each molecular dynamics run. The frame per second versus rendering time plot for each molecular dynamic interaction has been presented with docking results on blood brain barrier tight junction protein Zonula Occluden-1 (ZO-1) (Fig. 1A), Vascular Cell Adhesion Factor (VCAM) (Fig. 1B), human Toll-like receptor 8 (TLR8) (Fig. 2). The molecular docking experiments also demonstrates specificity of Spike peptide epitopes to form complex with human astrocyte specific protein N-myc downstream-regulated gene 2 (NDRG2) (Fig. 3A) and glial specific calcium regulator protein Apo-S100B (Fig. 3B).

Consequences of the hypothesis and discussion

The molecular dynamics (md) and docking experiments provide clear demonstrations on mechanism of interaction between Spike epitopes (1–60 and 241–300) and selected blood brain barrier protein Zo, innate immune responder TLR8 and brain derived glial cell proteins NDRG2 and Apo-S100B. The interaction profile indicates of SARS-COV-2 in blood brain barrier endothelium and cause inflammation in brain. The use of md method is a new way to identify interaction between homologous as well as non-homologues proteins on the basis of atom-to-atom alignment profile between two interacting proteins. The computational approach with md has been used to demonstrate mode of action of natural compound as possible drug and therapeutics in cancer [22,23]. Recently, therapeutic importance of human antimicrobial peptide LL-37 for COVID has been analyzed by md methods [24]. In the aspect, our observations provide new findings on Spike protein action on selected proteins in human brain.

The blood brain barrier (BBB) composed of endothelial cells, astrocyte-foot process and axons – all play vital role in maintaining CNS integrity. The junctions between the BBB cells selectively pass nutrients and small molecules from periphery to CNS. Our findings (Fig. 1A and B) that, viral spike epitopes [1–60: M1Lys60 and 241–300: Ala240-Glu300] form complex with tight junction protein Zo-1 and integrin VCAM-1, suggest a mechanism of Spike peptides on viral entry to CNS through BBB. The Spike peptide interaction pattern with human TLR8 (Fig. 2) is another critical observation showing involvement of TLR8. The elevated expression of VCAM1 is demonstrated in microglia in brain lesions of multiple sclerosis patients [25,26]. The possibility that, chronic inflammation in brain through interaction between Spike epitope and VCAM1 integrin leading to autoimmune onset of multiple sclerosis cannot be ignored in aging population. We found Spike peptides bind with astrocyte activation protein NDRG2 (tumor suppressor protein and stress response gene product). The elevated production of this protein shows activation of astrocyte and presence of abnormal synapic glutamate during neurodegenerative diseases and neuropathic pain [27,28]. We pursue these findings to determine specific binding region of SARS-COV-2 Spike peptides for the receptor(s) present in human brain and develop immunotherapy.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

I (S.D.G) acknowledge NeuroDrug Research LLC. and Biology divi- sion, Trident Technical College, Charleston for resources.

Consent statement/ethical approval

There is no animal model or human subject involved in the manuscript. The consent statement/ ethical approval is not required.

Funding statement

The research is supported by internal funding from NeuroDrug Research LLC. There is no Gov’t or other fund associated with the project.

References

[1] Kniep I, Heinemann A, Edler C, Sperhake JP, Ondruschka B, et al. COVID-19 lung findings in post-mortem computed tomography COVID-19-lungen in der post-mortem-computertomographie. Rechtsmedizin (Berl) 2021;31(2):145–7.
[2] Ojha V, Mani A, Pandey NN, Sharma S, Kumar S, CT in coronavirus disease 2019 (COVID-19): a systematic review of case CT findings in 4410 adult patients. Eur Radiol 2020;30(9):1629–38.
[3] Long B, Brady WJ, Koyman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020;38(7):1504–7.
[4] Severe Covid GG, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Alibillos A, et al. Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med 2020;383(16):1522–34.
[5] Valenti I, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, et al. Chromosome 3 cluster rs13895942 variants link complement activation with severe COVID-19. J Autoimmun 2021;117:102595. https://doi.org/10.1016/j.jaut.2021.102595.
[6] Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jeli, I et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMRPRSS2 polymorphism analysis. BMC Med 2020;18(1). https://doi.org/10.1186/s12910-019-0325-3.
[7] Littler R, Campagna M, Deidda S, Angioni G, Cirpi S, Melis M, et al. Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-Cov-2 infection and severity of the disease course. The Sardinian experience. Front Immunol 2020;11. https://doi.org/10.3389/fimmu.2020.006588.
[8] Ng WH, Tipih T, Makoah NV, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients a systematic review and meta-analysis. mBio 2021;12(1). https://doi.org/10.1128/mBio.03647-20.
[9] Mulchandani R, Lyngdell T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest 2021;51(1). https://doi.org/10.1111/eci.13429.
[10] Rogers JP, Chesney E, Oliver D, Pollack TA, McGuire P, Fass-Poli P, et al. Psychiatric and neurophysiological presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020;7(7):611–27.
[11] Percetti GA, Nalla AK, Huang M-L, Zhi H, Wei Y, Stensland I, et al. Validation of SARS-CoV-2 detection across multiple specimen types. J Clin Virol 2020;128: 104438. https://doi.org/10.1016/j.jcv.2020.104438.
[12] Morgello S. Coronaviruses and the central nervous system. J Neurovirol 2020;26 (4):459–73.
[13] Al-Dalahmah O, Thakur KT, Nordvig AS, Roth W, Lignelli A, et al. Neurodegeneration and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage. Acta Neuropathol Commun 2020;8(1). https://doi.org/10.1186/s40478-020-01024-2.
[14] Reynolds JL, Mabajan SD. SARS-COV2 alters blood brain barrier integrity contributing to neuro-inflammation. J Neuroimmune Pharmacol 2021;16(1):4–6.
[15] Buckhagen TG, DeOre BI, Baldwin-Leclair A, Bullock TA, McGary HM, Khan M et al. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol Dis 2020;146:105131. https://doi.org/10.1016/j.nbd.2020.105131.
[16] Matschie J, Lijtgehazman M, Haged C, Sperhake JP, Schröder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020;19(11):939–69.
[17] Vargas G, Medeiro Geraldo LH, Gedeão Salomão N, Viana Paes M, Regina Souza Lima F, Carvalho Alcantara Gomes F. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: insights and perspectives. Brain Behav Immunol 2020;77:101027. https://doi.org/10.1016/j.bbi.2020.101027.
[18] Wang JH, Pepsinsky RB, Stehle T, Liu JH, Karpusas M, Browning B, et al. The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): a cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1- alpha 4 integrin interaction. Proc Natl Acad Sci U S A 1995;92(12):5714–8.
[19] Tani H, Ohzu T, Shibata T, Miyaki K, Shimaizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 2013;339(6126): 1426–9.
[20] Hwang J, Kim Y, Kang HB, Jarozewskii L, Deacon AM, Lee H, et al. Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor. J Biol Chem 2011;286(14):12450–60.
[21] Drohat AG, Tjandra N, Baldixser DM, Weber DJ. The use of dipolar couplings for determining the solution structure of rat apo-S10BD8(betabeta). Proteins 1999;38(4):399–409.
[22] Alpsoy A, Utturkar SM, Carter BC, Dhiman A, Torregrossa-Allen SE, Currie MP, et al. BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression. Cancer Res 2021;81(4):820–33.
[23] Lokhande KB, Nagar S, Swamy KV. Molecular interaction studies of Denguein and its derivatives with Cyclin D1 and Cyclin E in cancer cell signaling pathway: the computational approach. Sci Rep 2019;9(1):1778.
[24] Lokhande KB, Banerjee T, Swamy KV, Ghosh P, Deshpande M. An in silico scientific basis for LL-37 as a therapeutic for Covid-19. Proteins 2021.
[25] Peterson JW, Bo L, Mork S, Chang A, Ransohoff RM, Trapp BD. VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropathol Exp Neurol 2002;61(6):539–46.

[26] Haarmann A, Nowak E, Deiss A, van der Pol S, Monoranu CM, Kooij G, et al. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin alpha-4-transduced outside-in signalling. Acta Neuropathol 2015;129(5):639–52.

[27] Flügge G, Araya-Callis C, Garea-Rodriguez E, Stadelmann-Nessler C, Fuchs E. NDRG2 as a marker protein for brain astrocytes. Cell Tissue Res 2014;357(1):31–41.

[28] Schonkeren SL, Massen M, van der Horst R, Koch A, Vaes N, Melotte V. Nervous NDRGs: the N-myc downstream-regulated gene family in the central and peripheral nervous system. Neurogenetics 2019;20(4):173–86.